SLC7A5 Antibody - #DF8065

(6)   (7)  
Product: SLC7A5 Antibody
Catalog: DF8065
Description: Rabbit polyclonal antibody to SLC7A5
Application: WB IHC IF/ICC
Reactivity: Human, Mouse
Prediction: Pig, Zebrafish, Bovine, Sheep, Rabbit, Chicken, Xenopus
Mol.Wt.: 55 kDa; 55kD(Calculated).
Uniprot: Q01650
RRID: AB_2841420

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:1000-3000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse
Prediction:
Pig(91%), Zebrafish(82%), Bovine(82%), Sheep(82%), Rabbit(82%), Chicken(82%), Xenopus(82%)
Clonality:
Polyclonal
Specificity:
SLC7A5 Antibody detects endogenous levels of total SLC7A5.
RRID:
AB_2841420
Cite Format: Affinity Biosciences Cat# DF8065, RRID:AB_2841420.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

4F2 LC; 4F2 light chain; 4F2LC; CD98; CD98 light chain; CD98LC; D16S469E; DC49; E16; hLAT1; Integral membrane protein E16; L type amino acid transporter; L type amino acid transporter 1; L-type amino acid transporter 1; Large neutral amino acids transporter 1; Large neutral amino acids transporter; Large neutral amino acids transporter small subunit 1; LAT1; LAT1_HUMAN; Membrane protein E16; MPE16; Slc7a5; Sodium independent neutral amino acid transporter; Sodium independent neutral amino acid transporter LAT1; Solute carrier family 7 (cationic amino acid transporter y+ system) member 5; Solute carrier family 7 member 5; TA1; Tumor associated protein 1; y+ system cationic amino acid transporter;

Immunogens

Immunogen:
Uniprot:

Q01650(LAT1_HUMAN) >>Visit HPA database.

Gene(ID):
SLC7A5(8140)
Expression:
Q01650 LAT1_HUMAN:

Detected in placenta, in the syncytiotrophoblast layer (at protein level) (PubMed:11389679). Expressed abundantly in adult lung, liver, brain, skeletal muscle, placenta, bone marrow, testis, resting lymphocytes and monocytes, and in fetal liver. Weaker expression in thymus, cornea, retina, peripheral leukocytes, spleen, kidney, colon and lymph node. During gestation, expression in the placenta was significantly stronger at full-term than at the mid-trimester stage. Also expressed in all human tumor cell lines tested and in the astrocytic process of primary astrocytic gliomas. Expressed in retinal endothelial cells and in the intestinal epithelial cell line Caco-2.

Sequence:
MAGAGPKRRALAAPAAEEKEEAREKMLAAKSADGSAPAGEGEGVTLQRNITLLNGVAIIVGTIIGSGIFVTPTGVLKEAGSPGLALVVWAACGVFSIVGALCYAELGTTISKSGGDYAYMLEVYGSLPAFLKLWIELLIIRPSSQYIVALVFATYLLKPLFPTCPVPEEAAKLVACLCVLLLTAVNCYSVKAATRVQDAFAAAKLLALALIILLGFVQIGKGDVSNLDPNFSFEGTKLDVGNIVLALYSGLFAYGGWNYLNFVTEEMINPYRNLPLAIIISLPIVTLVYVLTNLAYFTTLSTEQMLSSEAVAVDFGNYHLGVMSWIIPVFVGLSCFGSVNGSLFTSSRLFFVGSREGHLPSILSMIHPQLLTPVPSLVFTCVMTLLYAFSKDIFSVINFFSFFNWLCVALAIIGMIWLRHRKPELERPIKVNLALPVFFILACLFLIAVSFWKTPVECGIGFTIILSGLPVYFFGVWWKNKPKWLLQGIFSTTVLCQKLMQVVPQET

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
91
Bovine
82
Sheep
82
Xenopus
82
Zebrafish
82
Chicken
82
Rabbit
82
Horse
73
Dog
73
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q01650 As Substrate

Site PTM Type Enzyme
K7 Ubiquitination
K19 Ubiquitination
K25 Ubiquitination
K30 Ubiquitination
S31 Phosphorylation
S35 Phosphorylation
T45 Phosphorylation
S225 Phosphorylation
S354 Phosphorylation
T507 Phosphorylation

Research Backgrounds

Function:

The heterodimer with SLC3A2 functions as sodium-independent, high-affinity transporter that mediates uptake of large neutral amino acids such as phenylalanine, tyrosine, L-DOPA, leucine, histidine, methionine and tryptophan. Functions as an amino acid exchanger. May play a role in the transport of L-DOPA across the blood-brain barrier (By similarity). May act as the major transporter of tyrosine in fibroblasts (Probable). May mediate blood-to-retina L-leucine transport across the inner blood-retinal barrier (By similarity). Can mediate the transport of thyroid hormones triiodothyronine (T3) and thyroxine (T4) across the cell membrane. When associated with LAPTM4B, the heterodimer formed by SLC3A2 and SLC7A5 is recruited to lysosomes to promote leucine uptake into these organelles, and thereby mediates mTORC1 activation. Involved in the uptake of toxic methylmercury (MeHg) when administered as the L-cysteine or D,L-homocysteine complexes. Involved in the cellular activity of small molecular weight nitrosothiols, via the stereoselective transport of L-nitrosocysteine (L-CNSO) across the membrane.

Subcellular Location:

Apical cell membrane>Multi-pass membrane protein. Cell membrane>Multi-pass membrane protein. Lysosome membrane>Multi-pass membrane protein.
Note: Located to the plasma membrane by SLC3A2/4F2hc (PubMed:9751058). Localized to the apical membrane of placental syncytiotrophoblastic cells (PubMed:11742812). Recruited to lysosomes by LAPTM4B (PubMed:25998567). Expressed in both luminal and abluminal membranes of brain capillary endothelial cells (By similarity).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Detected in placenta, in the syncytiotrophoblast layer (at protein level). Expressed abundantly in adult lung, liver, brain, skeletal muscle, placenta, bone marrow, testis, resting lymphocytes and monocytes, and in fetal liver. Weaker expression in thymus, cornea, retina, peripheral leukocytes, spleen, kidney, colon and lymph node. During gestation, expression in the placenta was significantly stronger at full-term than at the mid-trimester stage. Also expressed in all human tumor cell lines tested and in the astrocytic process of primary astrocytic gliomas. Expressed in retinal endothelial cells and in the intestinal epithelial cell line Caco-2.

Subunit Structure:

Disulfide-linked heterodimer with the amino acid transport protein SLC3A2/4F2hc. Interacts with LAPTM4B; this recruits the heterodimer formed by SLC3A2 and SLC7A5 to lysosomes to promote leucine uptake into these organelles and is required for mTORC1 activation.

Family&Domains:

Belongs to the amino acid-polyamine-organocation (APC) superfamily. L-type amino acid transporter (LAT) (TC 2.A.3.8) family.

Research Fields

· Environmental Information Processing > Signal transduction > mTOR signaling pathway.   (View pathway)

· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer.   (View pathway)

References

1). Resetting amino acid metabolism of cancer cells by ATB0,+-targeted nanoparticles for enhanced anticancer therapy. Bioactive Materials (PubMed: 34820552) [IF=18.9]
2). Aurka deficiency in the intestinal epithelium promotes age-induced obesity via propionate-mediated AKT activation. International Journal of Biological Sciences (PubMed: 33867847) [IF=9.2]

Application: WB    Species: Mice    Sample: intestines

Figure 4 p-AKT promoted lipid metabolism and nutrient absorption in the intestine of Aurkaf/+;VillinCre/+ mice. (A, B) Lipid metabolism- and nutrient absorption-related mRNA and protein levels of were measured in the intestines of Aurkaf/+;VillinCre/+ mice. The graphs show the mean ± SEM of one of three independent experiments. (n=3 mice per group). *, P < 0.05. **, P <0.01. (C, D, E, F) The relative length and width of crypts and villi were measured by ImageJ software. The histogram shows the mean ± SEM. (G) The ratio of villi to crypt length in the intestine. (H, I) The concentrations of IL-6 and IL-1β in the serum were measured by ELISA. The bar graphs show the mean ± SEM of one of two independent experiments that included five groups of mice. *P <0.05. (J, K) H&E staining and CD3 immunostaining of the intestines of Aurkaf/+and Aurkaf/+;VillinCre/+ mice. The quantitative data are shown on the right.
3). The organic zinc with moderate chelation strength enhances the expression of related transporters in the jejunum and ileum of broilers. Poultry Science (PubMed: 36680861) [IF=4.4]

Application: WB    Species: broilers    Sample: jejunum

Figure 1 Representative immunoblots of ZnT1, ZnT4, ZnT5, ZnT7, ZnT9, ZIP3, ZIP5, B0AT1, LAT1, y+LAT2, rBAT and PepT1 in the jejunum of broilers at 28 (A) and 39 d (B) of age. ZnT1, zinc transporter 1; ZnT4, zinc transporter 4; ZnT5, zinc transporter 5; ZnT7, zinc transporter 7; ZnT9, zinc transporter 9; ZIP3, Zrt-irt-like protein 3; ZIP5, Zrt-irt-like protein 5; B0AT1, B-0-system neutral amino acid co-transporter; LAT1, L-type amino acid transporter 1; y+LAT2, y+L-type amino acid transporter 2; rBAT, b0,+-type amino acid transporter; PepT1, peptide-transporter 1; ZnS, Zn sulfate; Zn-Prot M, Zn proteinate with moderate chelation strength (Qf = 51.6).
4). Organic zinc with moderate chelation strength enhances zinc absorption in the small intestine and expression of related transporters in the duodenum of broilers. Frontiers in Physiology (PubMed: 35936908) [IF=4.0]

Application: WB    Species: broilers    Sample:

FIGURE 3 Effect of dietary Zn source on the protein expression levels of Zn, amino acid, and small peptide transporters in the duodenum of broilers at 28 days of age. Values are means ± SE, (n = 7/8). Lacking the same letters (a, b, and c) means significant differences, p < 0.05. ZnT1, zinc transporter 1; ZnT4, zinc transporter 4; ZnT5, zinc transporter 5; ZnT7, zinc transporter 7; ZnT9, zinc transporter 9; ZIP3, Zrt-irt-like protein 3; ZIP5, Zrt-irt-like protein 5; B0AT1, B-0-system neutral amino acid co-transporter; LAT1, L-type amino acid transporter 1; y + LAT2, y + L-type amino acid transporter 2; rBAT, b0,+-type amino acid transporter; PepT1, peptide-transporter 1; Zn-Prot M, Zn proteinate with moderate chelation strength (Qf = 51.6). The protein expression levels were calculated as the relative quantities (RQs) of the target gene protein to the β-tubulin protein.
5). Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[18F]FGln PET Imaging. Molecular Imaging and Biology (PubMed: 30850970) [IF=3.1]

Application: WB    Species: mouse    Sample: shASCT2 and shControl cells and tumor tissues

Fig. 4. |The uptake of 4-[18F]FGln reduced in ASCT2 knockdown tumors and cells and analysis of ASCT2 and LAT1 proteins after shRNA knockdown. a 4-[18F]FGln uptake in shASCT2-IMR-32 showed lower uptake than that in shControl-IMR-32, while[18F]FDG uptake showed no significant difference during the 120 min. b Relative mRNA expression of ASCT2 was calculated by 2−△△Ct method, and a reduced expression was observed after shASCT2 knockdown; ASCT2 expression showed a significant difference between in shASCT2 and shControl cells and tumor tissues. cASCT2 knockdown had no significant effect on the expression of LAT1 protein.
6). Self-assembled nanoparticles with bilirubin/JPH203 alleviate imiquimod-induced psoriasis by reducing oxidative stress and suppressing Th17 expansion. Chemical Engineering Journal

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.